The crash is huge: The profit of the German biotech star BioNTech fell by almost 95 percent in the first half of the year. A bigger alarm signal is hard to imagine, the question arises: Does the company of the two founders Uğur Şahin (57) and Özlem Türeci (56) have a business model at all?
One thing is clear: the potential is still enormous, if only because of the more than 20 billion euros that the Corona business has flushed into the coffers of the Mainz-based company. The ambition of Türeci and Şahin is also enormous. Their goal, they told mm reporter Dietmar Palan, was to build up the "Apple of medicine". Above all, they want to revolutionize cancer therapy with their mRNA technology.
How realistic is this in view of the new facts? And what are the decisive criteria that determine the success or failure of what is currently probably the largest innovation project of a German company? Palan discusses this in this podcast in an interview with editor-in-chief Sven Clausen.
In the podcast "Das Thema", editor-in-chief Sven Clausen provides weekly information on the internal state of research on a topic that is crucial for the German economy. You can subscribe to the podcast via manager magazin as well as on Spotify, Apple, Deezer and Google.
Soc